The National Pharmaceutical Pricing Authority (NPPA) Explained

The National Pharmaceutical Pricing Authority (NPPA) is the Government of India body, established in 1997, that fixes and revises the ceiling prices of scheduled essential medicines under the Drugs (Prices Control) Order and monitors the prices and availability of medicines and certain medical devices across the country. In simple terms, the NPPA is the agency that makes sure that the medicines most people depend on are not sold above a legally fixed maximum price.

The Authority works under the Department of Pharmaceuticals in the Ministry of Chemicals and Fertilizers. Its work touches ordinary households directly, because it decides how much a patient can be charged for medicines on the National List of Essential Medicines, and it has also capped the prices of devices such as coronary stents and knee implants. This explainer covers how the NPPA works, what it controls and what it leaves alone. It was last reviewed on 17 October 2026.

Key Takeaways

• The National Pharmaceutical Pricing Authority was set up on 29 August 1997 to take over the work of fixing and revising medicine prices under the Drugs (Prices Control) Order.
• The NPPA fixes a ceiling price, not a fixed price, for each scheduled formulation; a seller may charge less than the ceiling but never more, apart from applicable taxes.
• Scheduled medicines are those listed in the First Schedule of the DPCO, 2013, which is drawn from the National List of Essential Medicines.
• Prices of non-scheduled medicines are not fixed, but manufacturers are not allowed to raise the maximum retail price by more than 10 per cent in any twelve-month period without facing action.
• The NPPA has capped the prices of coronary stents and knee implants, and it is also the body that recovers overcharged amounts from manufacturers, along with interest.
• The NPPA does not approve drugs for sale or check their quality; those tasks belong to the Central Drugs Standard Control Organisation (CDSCO) and state drug regulators.

What is the National Pharmaceutical Pricing Authority?

The National Pharmaceutical Pricing Authority is an independent price-regulating body of the Government of India that implements the Drugs (Prices Control) Order and ensures the availability of medicines at reasonable prices. It was constituted in August 1997 through an executive resolution of the Government of India rather than a standalone Act of Parliament.

Its legal power comes from the Essential Commodities Act, 1955, under which the Central Government issues the Drugs (Prices Control) Order. The Authority acts as the implementing agency for that order, takes decisions on price fixation and revision, and answers to the Department of Pharmaceuticals.

The creation of the NPPA was meant to separate technical price-fixing from the day-to-day administrative machinery of the ministry, giving it a specialised, data-driven focus. It is staffed by officials and technical experts, including economists, pharmacologists and statisticians, who handle price calculations and market monitoring.

Why was the NPPA created?

The NPPA was created to bring professional, transparent price regulation to the pharmaceutical sector, as the government moved towards a more market-oriented drug policy in the 1990s. Until then, price control was carried out directly by the ministry under successive Drug Price Control Orders.

India has a history of controlling medicine prices that stretches back to the 1960s and 1970s. Orders issued in 1970, 1979, 1987 and 1995 progressively changed the extent of control. The number of price-controlled drugs fell sharply after the 1979 and 1987 orders as policy shifted to encourage domestic manufacture and competition.

The 1995 order and the creation of the NPPA reflected that shift. The goal was not to control every drug, but to ensure that essential medicines remain affordable while the rest of the market operates with limited oversight.

What is the Drugs (Prices Control) Order (DPCO)?

The Drugs (Prices Control) Order is the legal instrument, issued by the Central Government under the Essential Commodities Act, 1955, that gives the NPPA its powers to cap and monitor medicine prices. The version in force today is the DPCO, 2013, which replaced the 1995 order.

The 2013 order followed the National Pharmaceutical Pricing Policy, 2012. It made an important change in approach: rather than controlling the prices of bulk drugs on the basis of cost, it moved to a market-based method for scheduled formulations. This means that the ceiling is derived from what the market is already charging.

The order covers:

• The list of scheduled formulations whose prices are directly controlled.
• The method used to calculate ceiling prices.
• Rules for non-scheduled drugs, including the cap on yearly increases.
• Powers to recover overcharged sums, and penalties under the Essential Commodities Act.
• Reporting duties for manufacturers, importers and distributors.

How does the NPPA fix the ceiling price of a medicine?

The NPPA fixes the ceiling price of a scheduled formulation by taking the simple average of the price to retailer of all brands and generics with a market share of at least one per cent, then adding a retailer margin of 16 per cent. This market-based method has been used since the DPCO, 2013, came into force.

The steps are straightforward:

• The NPPA identifies the formulation and strength listed in the First Schedule.
• It obtains market data from a recognised pharmaceutical market research firm, identifying brands with at least one per cent share.
• It calculates the simple average of the price to retailer of those brands.
• It adds 16 per cent to account for the retailer margin, which gives the ceiling price excluding goods and services tax.
• It notifies the price in the Gazette of India, after which it becomes legally binding.

Manufacturers selling above the ceiling must reduce their price. A manufacturer that already sells below the ceiling is not forced to raise it. The ceiling price can be revised, and the Authority also publishes retail prices of individual brands where needed.

What is the National List of Essential Medicines?

The National List of Essential Medicines (NLEM) is a list prepared by the Ministry of Health and Family Welfare that identifies medicines considered essential for the priority health needs of the population. It forms the basis of the First Schedule of the DPCO, which in turn defines which medicines are price-controlled.

The list has been revised several times, with versions published in 1996, 2003, 2011, 2015 and 2022. The 2015 list included 348 medicines and the 2022 list included 384, though these figures can change with later revisions and should be checked against the current notification.

Inclusion in the NLEM is decided on criteria such as disease burden, efficacy, safety, cost-effectiveness and availability. A medicine added to the list becomes eligible for ceiling price fixation, while a medicine dropped from the list no longer remains in the First Schedule. This link explains why debates over the NLEM often centre on which drugs get price protection.

What is the difference between scheduled and non-scheduled medicines?

Scheduled medicines are those listed in the First Schedule of the DPCO and are subject to a legally fixed ceiling price, while non-scheduled medicines are everything else and are subject only to an annual price increase limit. Understanding this split is the key to understanding what the NPPA can and cannot do.

The NPPA has also, in some instances, used special provisions of the DPCO to bring non-scheduled medicines under tighter control, for example by capping trade margins on a group of anticancer drugs in 2019. The use of such provisions is meant for situations of public interest.

How does the NPPA control the prices of medical devices?

The NPPA controls the prices of certain medical devices by treating them as drugs under the Drugs and Cosmetics Act and then applying the price controls available under the DPCO. Two high-profile examples are coronary stents and knee implants.

In February 2017, the NPPA capped the prices of coronary stents, bringing them under price control as part of a wider move after the stents were added to the NLEM. Later in 2017, it capped the price of knee implants and reduced the cost of total knee replacement materially, with separate limits for different types of implants.

From April 2020, all medical devices were notified as drugs under the Drugs and Cosmetics Act, which widened the NPPA’s ability to monitor the prices of every device in the market. Even where devices are not under ceiling prices, the NPPA can ask manufacturers to restrict annual price increases to the 10 per cent limit that applies to non-scheduled products.

What happens when a company overcharges?

When a company charges more than the notified ceiling price, the NPPA issues a demand notice and recovers the overcharged amount from the manufacturer along with interest. The recovery is made on the basis of the price actually charged to consumers compared with the ceiling price.

The process usually runs in four stages:

• Detection: Overcharging is identified through monitoring, state drug controllers’ reports or consumer complaints.
• Notice: The company is given an opportunity to explain, supported by sales data.
• Order: The NPPA issues an order for deposit of the overcharged amount with interest.
• Recovery: If payment is not made, recovery may follow as arrears of land revenue, and the matter can be challenged in a High Court.

The money recovered is deposited with the Government and not paid directly to individual patients. The Essential Commodities Act also allows prosecution in serious cases, since selling above the controlled price is an offence under that Act.

How can a consumer complain about a medicine price?

A consumer can complain about overcharging for a medicine through the Pharma Jan Samadhan online grievance system run by the NPPA, or through the Pharma Sahi Daam mobile application. Both are available free of charge.

The Pharma Sahi Daam application also allows users to search the ceiling price and retail price of a scheduled medicine and compare alternatives with the same salt composition. A patient who finds a pharmacy charging more than the printed price can report it, and state drug controllers may also act.

Complaints are typically most useful when they include:

• The name, strength and batch number of the medicine.
• The price printed on the strip and the price charged.
• The name and address of the chemist and a copy of the bill.

How does the NPPA monitor supply and availability?

The NPPA monitors availability by tracking production and sales data, and it can direct a manufacturer to continue producing a scheduled drug if a shortage arises. Price control is only effective if the medicine remains available, so the Authority treats supply as part of its mandate.

It operates a network of Price Monitoring and Resource Units (PMRUs) in states and union territories, which collect market information and assist state governments. The NPPA also maintains an integrated database of manufacturers and products to support its decisions.

Manufacturers who plan to discontinue a scheduled formulation are required to give prior notice, so that the government can look at the impact on patients. This helps to prevent a situation in which a controlled medicine disappears from the shelf because it is less profitable.

What does the NPPA not do?

The NPPA does not approve new drugs, test the quality of medicines or regulate the prescribing practices of doctors. These responsibilities fall to other bodies, and confusing them is a common error.

• The Central Drugs Standard Control Organisation (CDSCO) approves new drugs and regulates clinical trials and imports.
• State drug controllers license manufacturers and sellers and enforce quality standards.
• The Ministry of Health and Family Welfare prepares the NLEM and sets health policy.
• The NPPA concerns itself only with price and availability.

Because the NPPA deals chiefly with scheduled medicines, a large share of the market, covering non-essential and newer drugs, remains outside direct price fixing. This is a central criticism from consumer groups, while industry bodies argue that price control can reduce investment and may discourage the supply of low-margin drugs.

Bottom Line

The National Pharmaceutical Pricing Authority is India’s price referee for essential medicines. It sets ceilings for scheduled drugs, watches the rest of the market and recovers money when sellers cross the line. Its power is bounded by the NLEM and by the DPCO, so it works best alongside quality regulators and well-informed consumers.

Frequently Asked Questions

What does the National Pharmaceutical Pricing Authority do?

The National Pharmaceutical Pricing Authority fixes and revises the ceiling prices of scheduled essential medicines and monitors the prices of all other medicines and certain medical devices. It also tracks the availability of medicines and recovers amounts charged above the legal limit. It works under the Department of Pharmaceuticals.

When was the NPPA established?

The NPPA was established on 29 August 1997 through a resolution of the Government of India. It was set up to implement the Drugs (Prices Control) Order in a more specialised and transparent manner. Its authority flows from the Essential Commodities Act, 1955.

What is a ceiling price?

A ceiling price is the maximum price, excluding taxes, at which a scheduled medicine can be sold to a consumer. Sellers may charge less than the ceiling but not more. The NPPA calculates it by averaging the price to retailer of brands with at least one per cent market share and adding a 16 per cent retailer margin.

Does the NPPA control the price of every medicine?

No, the NPPA directly fixes the prices only of scheduled medicines listed in the First Schedule of the DPCO, 2013. For all other medicines, it restricts yearly increases in the maximum retail price to 10 per cent. In special circumstances, it can use additional powers to cap prices or margins.

How can I report a medicine being sold above the ceiling price?

You can report overcharging through the Pharma Jan Samadhan grievance system or the Pharma Sahi Daam mobile application, both run by the NPPA. Keep the bill, the strip with the printed price and the batch details. State drug controllers can also take action against local sellers.

Is the NPPA responsible for drug quality?

No, the NPPA is responsible for pricing and availability, not quality or safety. Drug approvals are handled by the Central Drugs Standard Control Organisation, and licensing and quality enforcement are handled by state drug authorities. A patient with a quality concern should approach these bodies instead.

{“@context”:”https://schema.org”,”@graph”:[{“@type”:”FAQPage”,”mainEntity”:[{“@type”:”Question”,”name”:”What does the National Pharmaceutical Pricing Authority do?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”The National Pharmaceutical Pricing Authority fixes and revises the ceiling prices of scheduled essential medicines and monitors the prices of all other medicines and certain medical devices. It also tracks the availability of medicines and recovers amounts charged above the legal limit. It works under the Department of Pharmaceuticals.”}},{“@type”:”Question”,”name”:”When was the NPPA established?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”The NPPA was established on 29 August 1997 through a resolution of the Government of India. It was set up to implement the Drugs (Prices Control) Order in a more specialised and transparent manner. Its authority flows from the Essential Commodities Act, 1955.”}},{“@type”:”Question”,”name”:”What is a ceiling price?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”A ceiling price is the maximum price, excluding taxes, at which a scheduled medicine can be sold to a consumer. Sellers may charge less than the ceiling but not more. The NPPA calculates it by averaging the price to retailer of brands with at least one per cent market share and adding a 16 per cent retailer margin.”}},{“@type”:”Question”,”name”:”Does the NPPA control the price of every medicine?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”No, the NPPA directly fixes the prices only of scheduled medicines listed in the First Schedule of the DPCO, 2013. For all other medicines, it restricts yearly increases in the maximum retail price to 10 per cent. In special circumstances, it can use additional powers to cap prices or margins.”}},{“@type”:”Question”,”name”:”How can I report a medicine being sold above the ceiling price?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”You can report overcharging through the Pharma Jan Samadhan grievance system or the Pharma Sahi Daam mobile application, both run by the NPPA. Keep the bill, the strip with the printed price and the batch details. State drug controllers can also take action against local sellers.”}},{“@type”:”Question”,”name”:”Is the NPPA responsible for drug quality?”,”acceptedAnswer”:{“@type”:”Answer”,”text”:”No, the NPPA is responsible for pricing and availability, not quality or safety. Drug approvals are handled by the Central Drugs Standard Control Organisation, and licensing and quality enforcement are handled by state drug authorities. A patient with a quality concern should approach these bodies instead.”}}]}]}